More News! 10 Dec 2024 Biotech in 2024: A retrospective …step in and fill the gap China CDMOs will leave behind them, it does mean U.S. and perhaps European biotechs will have to rethink their supply chains. Fortunately, some events… December 10, 2024 - 14 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 First patient receives new immunotherapy drug for HIV in clinical trial …approved for the treatment of HIV. If started early, antiretroviral therapy (ART) provides people with HIV with a normal life expectancy, prevents immunodeficiency and stops the spread of the virus…. July 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 26 Feb 2025 New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis? …significant drop in pain intensity 44 hours post-operation. Additionally, its safety profile was comparable to placebo, with no adverse events related to the drug. Harold Minkowitz, primary investigator in the… February 26, 2025 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform …In comparison to intramuscular injections, which generate systemic immunity, this approach prevents infections from taking hold in the body by counteracting them at the point of entry. This has the… November 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Aug 2018 Update: Seaweed-Derived Treatment for Common Cold Approved in the EU …in the nose, which prevents cold viruses from attaching to and infecting cells, and soothes mucus membranes by keeping them moist. Previous Phase III results showed carragelose given on its… August 7, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 May 2024 Eight companies spearheading Philadelphia’s biotech industry …In 2024, Passage Bio reported positive interim results from the upliFT-D clinical trial for PBFT02. The data showed that the therapy was generally well-tolerated with no serious adverse events in… May 21, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2020 €30M Series A to Fund Spanish Biotech’s Anti-Metastasis Cancer Drug A Series A round closed by Barcelona-based startup Ona Therapeutics will finance the preclinical development of a drug that prevents cancer from spreading in the body by targeting the metabolism… June 17, 2020 - 2 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2016 Meet the French CEO who wants to Break Barriers to Drug Delivery …treat neurological disorders like Alzheimer’s disease, stroke and multiple sclerosis. However, the blood-brain barrier (BBB), which prevents most toxic molecules and infectious agents from entering the brain, also heavily restricts… October 10, 2016 - 5 minutesmins - By Marie Godar Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Gedea Biotech reports results from bacterial vaginosis trial …events observed among patients receiving pHyph treatment, and no safety concerns. Based on these results the company now continues the process for European CE mark approval of pHyph and further… October 11, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Nov 2023 Five companies shaping Texas’ growing biotech hubs …cells, and the overstimulation of the pathway can lead to tumor microenvironment hypoxia, which prevents tumor cells from being killed, and limits the effect of immunotherapies. The candidate is being… November 28, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 6 Sep 2021 Why We Desperately Need to Develop New Antifungals …many drugs, interactions between azoles and other drugs can contribute to adverse events such as liver toxicity. Echinocandins target glucan synthase, an enzyme in the cell wall of fungi that… September 6, 2021 - 10 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022 Poolbeg influenza trial successfully completed …close on schedule. No serious adverse events were reported. Poolbeg Pharma’s POLB 001 was found to be safe and well tolerated. Data analysis has commenced and full data read-out is… December 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email